Disseminated immune deposits in lupus erythematosus

Brentjens, Jan R.; Ossi, Elena; Albini, Boris; Sepúlveda, B; Kano, Kyoichi; Sheffer, John; Vasilion, Peter; Marine, Edward; Baliah, Tadla; Jockin, Hubert; Andres, Giuseppe A.

doi:10.1002/art.1780200408

Cited by 70 publications

(23 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The idiotype-positive patients are those numbered [1][2][3][4][5][6][7][8][9][10][11][12] in Table I. The results of their routine light histology, electron microscopy, and immunofluorescence microscopy, as well as the details of their idiotype deposition are shown in Table III The results of the light histology, electron microscopy, and immunofluorescence of the control groups are shown in Table IV.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Detection of cross-reactive anti-DNA antibody idiotypes on renal tissue-bound immunoglobulins from lupus patients.

Isenberg¹,

Collins²

1985

J. Clin. Invest.

129

View full text Add to dashboard Cite

Cross-reactive anti-DNA antibody idiotypes have been identified on tissue-bound immunoglobulins in a study of renal biopsies from 26 systemic lupus erythematosus (SLE) patients. 12 (46%) biopsies were shown to have one or both the idiotypes tested for by anti-idiotypic reagents. The idiotypes were identified in the glomerular basement membrane, the mesangial cell cytoplasm, and in focal tuft proliferations. In contrast, in none of 24 immunoglobulin-positive disease control biopsies could either idiotype be demonstrated. Blocking studies in two patients indicated that the idiotypes were on anti-DNA antibodies. These findings indicate that some tissue-bound autoantibodies are derived from related families of high-frequency germ line genes that are expressed in SLE patients. The potential role of anti-idiotypic therapy in SLE is discussed.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Some of these autoantibodies, notably those thought to be directed against single-and double-stranded DNA, have been shown to contribute to the formation of lesions in the kidney (2) and skin (3) of patients with SLE.…”

Section: Introductionmentioning

confidence: 99%

Detection of cross-reactive anti-DNA antibody idiotypes on renal tissue-bound immunoglobulins from lupus patients.

Isenberg¹,

Collins²

1985

J. Clin. Invest.

129

View full text Add to dashboard Cite

show abstract

“…27 In SLE patients, the pulmonary vessels of PAH have histologic features quite similar to those observed in lupus nephritis, especially proliferative glomerulonephritis. In this regard, the histologic evaluation of autopsied cases with active SLE revealed immune deposition in the vascular wall in all tissues examined, including kidney and lung, 28 suggesting that the inflammatory and careful monitoring of the efficacy is mandatory, and pulmonary vasodilators should be added if the treatment response is inadequate. In contrast, pulmonary vasodilators should be combined initially with first-line IS treatment in patients lacking predictors of a short-term response to IS treatment, such as the occurrence of PAH many years after the course of CTD, and severe hemodynamic impairment, as suggested by others.…”

Section: Discussionmentioning

confidence: 99%

Predictors of Favorable Responses to Immunosuppressive Treatment in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease

Yasuoka

Shirai

Tamura

et al. 2018

Circ J

View full text Add to dashboard Cite

Background:The potential efficacy of immunosuppressive (IS) treatment has been reported in patients with pulmonary arterial hypertension (PAH) associated with connective tissue disease (CTD), but its positioning in the treatment algorithm remains uncertain. The aim of this study was to identify predictors of favorable responses to first-line IS treatment. Methods and Results:This single-center retrospective study included 30 patients with PAH accompanied by systemic lupus erythematosus (SLE), mixed CTD (MCTD), or primary Sjögren's syndrome (SS) who received first-line IS treatment alone or in combination with pulmonary vasodilators. When short-term treatment response was defined as an improvement in World Health Organization functional class at 3 months, 16 patients (53%) were short-term responders. Simultaneous diagnosis of PAH and CTD, and the use of immunosuppressants, especially intravenous cyclophosphamide, in addition to glucocorticoids were identified as independent predictors of a short-term response (P=0.004 and 0.0002, respectively). Cumulative rates free of PAH-related death were better in short-term responders than non-responders (P=0.04), and were best in patients with a simultaneous diagnosis of PAH and CTD who were treated initially with a combination of glucocorticoids and immunosuppressants. Conclusions:Patients with a simultaneous diagnosis of PAH and CTD, including SLE, MCTD, and primary SS, should receive intensive IS treatment regimens to achieve better short-and long-term outcomes.

show abstract

“…CIC with anti-SSA antibodies could be selectively deposited in the lung and cause the initial response. The level of antinuclear antibodies eluted from lung tissue appears to be higher than in the serum, suggesting compartimentation in these sites, possibly related to the presence of autoantigen [14]. The effectiveness of plasmapheresis in patients with acute lupus pneumonia or with alveolar haemorrhage (AH) suggests the importance of autoantibodies in the pathophysiology of this pulmonary damage [15,16]; • the CIC deposits in human SLE prove their implication in the disease.…”

Section: Pathogenesis Of Lupusmentioning

confidence: 96%